| Item Type | Name |
|
Concept
|
Acute Disease
|
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Gastrointestinal Diseases
|
|
Concept
|
Graft vs Host Disease
|
|
Concept
|
Hepatic Veno-Occlusive Disease
|
|
Concept
|
Graft Survival
|
|
Concept
|
Chronic Disease
|
|
Concept
|
Disease Susceptibility
|
|
Concept
|
Graft Rejection
|
|
Concept
|
Hematologic Diseases
|
|
Concept
|
Hematopoietic Stem Cells
|
|
Concept
|
Nervous System Diseases
|
|
Concept
|
Primary Prevention
|
|
Concept
|
Recurrence
|
|
Concept
|
Stem Cells
|
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
|
Concept
|
Disease Management
|
|
Concept
|
Vascular Diseases
|
|
Concept
|
Stem Cell Transplantation
|
|
Concept
|
Neoplasm Recurrence, Local
|
|
Concept
|
Disease Progression
|
|
Concept
|
Hematopoietic Stem Cell Mobilization
|
|
Concept
|
Peripheral Blood Stem Cell Transplantation
|
|
Concept
|
Adult Stem Cells
|
|
Concept
|
Chemotherapy, Adjuvant
|
|
Concept
|
Secondary Prevention
|
|
Concept
|
Cord Blood Stem Cell Transplantation
|
|
Concept
|
Liver Diseases
|
|
Concept
|
Virus Diseases
|
|
Concept
|
Disease-Free Survival
|
|
Concept
|
Genetic Predisposition to Disease
|
|
Concept
|
Rare Diseases
|
|
Concept
|
Myelodysplastic-Myeloproliferative Diseases
|
|
Academic Article
|
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
|
|
Academic Article
|
Myelofibrosis with myeloid metaplasia: where is the biology leading us?
|
|
Academic Article
|
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
|
|
Academic Article
|
Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.
|
|
Academic Article
|
Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
|
|
Academic Article
|
Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease.
|
|
Academic Article
|
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
|
|
Academic Article
|
Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant.
|
|
Academic Article
|
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
|
|
Academic Article
|
Successful allogeneic transplantation of patients with suspected prior invasive mold infection.
|
|
Academic Article
|
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
|
|
Academic Article
|
Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions.
|
|
Academic Article
|
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.
|
|
Academic Article
|
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
|
|
Academic Article
|
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
|
|
Academic Article
|
Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.
|
|
Academic Article
|
Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity.
|
|
Academic Article
|
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
|
|
Academic Article
|
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
|
|
Academic Article
|
DNA repair genes, electromagnetic fields and susceptibility to acute leukemia?
|
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
|
Academic Article
|
Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome.
|
|
Academic Article
|
Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
|
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
|
Academic Article
|
Influence of related donor age on outcomes after peripheral blood stem cell transplantation.
|
|
Academic Article
|
Immune reconstitution after combined haploidentical and umbilical cord blood transplant.
|
|
Academic Article
|
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).
|
|
Academic Article
|
Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
|
|
Academic Article
|
A novel clofarabine bridge strategy facilitates allogeneic transplantation in patients with relapsed/refractory leukemia and high-risk myelodysplastic syndromes.
|
|
Academic Article
|
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.
|
|
Academic Article
|
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.
|
|
Academic Article
|
Beyond JAK inhibitor therapy in myelofibrosis.
|
|
Academic Article
|
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.
|
|
Academic Article
|
Age-related differences in disease characteristics and clinical outcomes in polycythemia vera.
|
|
Academic Article
|
Myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation.
|
|
Academic Article
|
Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
|
|
Academic Article
|
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era?
|
|
Academic Article
|
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
|
|
Academic Article
|
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
|
|
Academic Article
|
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.
|
|
Academic Article
|
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia.
|
|
Academic Article
|
Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
|
|
Academic Article
|
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
|
|
Academic Article
|
How I treat the blast phase of Philadelphia chromosome-negative myeloproliferative neoplasms.
|
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
|
Academic Article
|
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
|
|
Academic Article
|
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation.
|
|
Academic Article
|
Incorporating novel approaches in the management of MDS beyond conventional hypomethylating agents.
|
|
Academic Article
|
Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant.
|
|
Academic Article
|
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.
|
|
Academic Article
|
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
|
|
Academic Article
|
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study.
|
|
Academic Article
|
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.
|
|
Academic Article
|
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.
|
|
Academic Article
|
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
|
|
Academic Article
|
A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia.
|
|
Academic Article
|
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib.
|
|
Academic Article
|
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
|
|
Academic Article
|
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
|
|
Academic Article
|
Genomics of MPN progression.
|
|
Academic Article
|
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
|
|
Academic Article
|
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
|
|
Academic Article
|
Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022.
|
|
Academic Article
|
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
|
|
Academic Article
|
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
|
|
Academic Article
|
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.
|
|
Academic Article
|
SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It.
|
|
Concept
|
Chemotherapy-Induced Febrile Neutropenia
|
|
Academic Article
|
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
|
|
Academic Article
|
Cellular Composition and 5hmC Signature Predict the Treatment Response of AML Patients to Azacitidine Combined with Chemotherapy.
|
|
Academic Article
|
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
|
|
Academic Article
|
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
|
|
Academic Article
|
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis.
|